Coronavirus disease 2019 (COVID-19) vaccines deployed in the European Union (EU) and assessed by the European Medicines Agency (EMA) have been developed and approved in less than 12 months, still maintaining the safety at the standards requested for any newly approved medicine [1]. After three years of COVID-19 vaccines use in real-world settings and thousands of papers and reports produced, the safety profile still remains very high, and the overall benefits largely outweigh the risks [2]. According to the EMA close to 1 billion doses of vaccines have been administered in the European Economic Area (EEA) and most of the adverse reactions (ADRs) reported were mild and short-lived, with serious reactions being extremely rare [2].
